$114 Million is the total value of Athyrium Capital Management, LP's 6 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | Omeros Corpnote 5.250% 2/1 | $44,643,626 | -15.4% | 72,979,000 | +1.4% | 39.31% | +14.9% | |
| Sell | Biora Inc.note 7.250% 12/0 | $27,960,943 | -53.8% | 53,500,000 | -48.3% | 24.62% | -37.2% | |
| Buy | Biora Inc. | $23,717,584 | +263.6% | 10,929,762 | +545.0% | 20.89% | +393.5% | |
| Omeros Corpnote 6.250%11/1 | $11,255,556 | +2.0% | 11,005,000 | 0.0% | 9.91% | +38.4% | ||
| PBYI | PUMA BIOTECHNOLOGY INC | $4,713,260 | -25.5% | 1,792,114 | 0.0% | 4.15% | +1.1% | |
| OSMT | RVL PHARMACEUTICALS PLC | $1,264,399 | -84.5% | 14,600,444 | 0.0% | 1.11% | -79.0% | |
| Exit | Paratek Pharmaceuticals Inc.note 4.750% 5/0 | $0 | – | -9,000,000 | -100.0% | -5.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Amryt Pharma PLC | 10 | Q1 2023 | 46.3% |
| Progenity Inc. | 9 | Q4 2022 | 69.2% |
| Progenity Inc. | 8 | Q3 2023 | 39.2% |
| RVL PHARMACEUTICALS PLC | 8 | Q3 2023 | 11.5% |
| Societal CDMO Inc. | 8 | Q4 2022 | 3.1% |
| Omeros Corp | 7 | Q3 2023 | 39.3% |
| CAREMAX INC | 7 | Q4 2022 | 27.5% |
| Omeros Corp | 7 | Q3 2023 | 9.9% |
| PUMA BIOTECHNOLOGY INC | 7 | Q3 2023 | 4.2% |
| AEGERION PHARMACEUTICALS INC | 6 | Q1 2019 | 88.7% |
View Athyrium Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PROGENITY, INC. | August 27, 2021 | 4,211,977 | 2.7% |
View Athyrium Capital Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR/A | 2023-05-16 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Athyrium Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.